Adenocarcinoma: all 1,996 studies
Page 12 of 20. Open to participants first (369), then studies with results posted, then the rest; newest registration first within each.
- Novel MRI Techniques for Pancreatic CancerWithdrawnNCT04306861
- Magnetic Resonance Guided High Intensity Focused Ultrasound in Advanced Pancreatic Adenocarcinoma TreatmentCompletedNCT04298242Not applicable
- PDAC Peripheral and Portal Vein SamplingCompletedNCT04289961Not applicable
- Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric AdenocarcinomaCompletedNCT04281576Not applicable
- A Biomarker-driven Therapeutic Strategy for Esophageal Cancer Chemoradiotherapy in Patients With Resectable Adenocarcinoma of the ESophagus and Esophagogastric JunctionStatus unknownNCT04269083Not applicable
- Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric JunctionStatus unknownNCT04263870Phase 2
- Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line TreatmentCompletedNCT04263090Phase 1/2
- A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA MethylationWithdrawnNCT04262388Phase 2
- Trial of NanoDoce Intratumoral Injection in Renal Cell CarcinomaWithdrawnNCT04260360Phase 1
- Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.Status unknownNCT04258072Phase 1
- A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel AdenocarcinomaActive, not recruitingNCT04257461Phase 3
- CINSARC Genomic Signature as Predictor of Resectability of Ovarian AdenocarcinomaCompletedNCT04248231
- Efficacy of Chemopreventive Agents on Disease-free and Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma: The CAOS StudyActive, not recruitingNCT04245644
- KEBI-Cyto Study - Use of the Biocartis IdyllaCompletedNCT04236102Not applicable
- A Retrospective Validations Microsatellite Instability (MSI) Testing v Mismatch Repair (MMR) in Gastric AdenocarcinomaCompletedNCT04232020
- Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical CancerTerminatedNCT04230954Phase 2
- Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic CancerStatus unknownNCT04216758Phase 2
- Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Phase 2/3
- Prognostic Role of Positron Emission Tomography and Computed Tomography Parameters in Stage I Lung AdenocarcinomaCompletedNCT04202614
- Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric CancerStatus unknownNCT04202601Phase 1/2
- Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction AdenocarcinomaStatus unknownNCT04202484Phase 2
- Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung AdenocarcinomaCompletedNCT04201756Phase 2
- Maintaining Fitness During Neo-adjuvant Chemotherapy for Oesophago-gastric Cancer: a Feasibility StudyStatus unknownNCT04194463Not applicable
- Retrospective Study of Ramucirumab and Paclitaxel in Gastric or Gastroesophageal Junction AdenocarcinomaCompletedNCT04192734
- Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical StudyStatus unknownNCT04190745Phase 2
- PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric CancerStatus unknownNCT04174339Not applicable
- HRCT in Prediction of Tumor Invasion in GGO Lung Adenocarcinoma (ECTOP-1008)CompletedNCT04165759
- A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction CancerCompletedNCT04161781
- RICE: Radio-Immuno-Chemotherapy of Cancer of the EsophagusActive, not recruitingNCT04159974Phase 2
- Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract AdenocarcinomaStatus unknownNCT04156958Phase 2
- Classification of Adenocarcinoma of the Esophagogastric JunctionStatus unknownNCT04151524
- A Study of Extended Total Mesopancreas Excision(eTME) for Pancreatic Head Adenocarcinoma.Status unknownNCT04147403
- Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal AdenocarcinomaCompletedNCT04146441Phase 2
- Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal AdenocarcinomasCompletedNCT04145297Phase 1
- Pseudo Continent Perineal Colostomy vs Permanent Left Iliac Colostomy After Abdominoperineal Resection for Ultra Low Rectal AdenocarcinomaCompletedNCT04141566
- Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction AdenocarcinomaStatus unknownNCT04140318Phase 2
- MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal AdenocarcinomaWithdrawnNCT04134468Phase 2
- Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter StudyStatus unknownNCT04122833
- Study of the Apatinib Combine With POF Versus POF in Gastric CancerStatus unknownNCT04121039Phase 2
- Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal CancerWithdrawnNCT04119830Phase 2
- PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic CancerCompletedNCT04119362
- Should a Standard Lymphadenectomy Include the No. 16 Lymph Nodes for Patients With Pancreatic Head Adenocarcinoma.Active, not recruitingNCT04115527Not applicable
- Study for the Efficacy and Security Analysis in the Protection of Ileocolic Anastomosis Conducted in Laparoscopic Right Hemicolectomy Because of Colon Cancer, Using a NHS-PEG Coated Collagen Patch.Status unknownNCT04109105
- PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction AdenocarcinomaStatus unknownNCT04098796Phase 2
- STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic AdenocarcinomaCompletedNCT04098432Phase 1/2
- A Phase 2 Trial for Men With Metastatic Prostatic AdenocarcinomaCompletedNCT04090775Phase 2
- Optimisation of Radiotherapy in Rectal Cancer (ORREC)Status unknownNCT04090450
- Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic CancerNo longer availableNCT04087889
- A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) AdenocarcinomaCompletedNCT04086758Phase 1
- The Detection of EGFR Mutations in Liquid Based Cytology SamplesCompletedNCT04086680
- Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate CancerTerminatedNCT04085991Phase 2
- EGFR-targeted Therapy for Gastric CancerStatus unknownNCT04077255Phase 2
- First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate CancerTerminatedNCT04077021Phase 1
- Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL AdenocarcinomaActive, not recruitingNCT04069273Phase 2
- The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.Status unknownNCT04065282Phase 2
- Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized StudyCompletedNCT04065139Phase 2
- Prediction of the Risk of Biochemical Relapse After Radical Prostatectomy for Prostate Cancer Using Radomics on Pre-therapeutic MRICompletedNCT04063800
- Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEGActive, not recruitingNCT04062656Phase 2
- GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic AdenocarcinomaTerminatedNCT04060342Phase 1
- SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic CancerCompletedNCT04050085Phase 1
- Adjuvant PIPAC in Gastric Cancer PatientsCompletedNCT04047004Phase 1
- Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)TerminatedNCT04046887Phase 1
- Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma HistologyCompletedNCT04046614Phase 1/2
- The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.WithdrawnNCT04045730Phase 2
- Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal CancerTerminatedNCT04044430Phase 1
- Nutritional Supplementation in Reducing Complications in Patients With Locally Advanced Esophageal Cancer Undergoing Chemotherapy, Radiation Therapy, and/or SurgeryWithdrawnNCT04029857Phase 3
- Nalirinox Neo-pancreas RAS Mut ctDNA StudyStatus unknownNCT04010552Phase 2
- PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric AdenocarcinomaStatus unknownNCT04006821Phase 2
- Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.Active, not recruitingNCT04006262Phase 2
- Human Intestinal Microbiome and Surgical Outcomes in Patients Undergoing Colorectal Cancer SurgeryStatus unknownNCT04005118
- Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal AdenocarcinomaStatus unknownNCT03995017Phase 1/2
- Prospective Study of Oncologic Outcomes After Laparoscopic Modified Complete Mesocolic Excision for Non-metastatic Right Colon Cancer [PIONEER Study]Status unknownNCT03992599
- S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant AscitesStatus unknownNCT03990103Phase 2
- Surgical Management of Multiple Mucoepidermoid Carcinoma and AdenocarcinomaCompletedNCT03988959Not applicable
- Noncurative Endoscopic Resection of Colorectal AdenocarcinomaCompletedNCT03987828
- Financial Navigation Intervention in Improving Financial and Clinical Outcomes in Patients With Newly Diagnosed Gastric or Gastroesophageal Junction AdenocarcinomaCompletedNCT03986502Not applicable
- Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal JunctionStatus unknownNCT03986385Phase 3
- Germline Mutations in Pancreatic AdenocarcinomaCompletedNCT03982446
- Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid TumorsWithdrawnNCT03982173Phase 2
- Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic AdenocarcinomaTerminatedNCT03974854Phase 2
- Impact of Multidisciplinary and Radiologic Review on Outcome of Pancreatic Cancer Patients: an Observational StudyCompletedNCT03973736
- Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic CancerCompletedNCT03970252Early Phase 1
- Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal AdenocarcinomaStatus unknownNCT03966118Phase 2
- Effect of Treatment on Work Experience in Patients With Stage I-III Prostate CancerCompletedNCT03963739
- Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction AdenocarcinomaActive, not recruitingNCT03959293Phase 2
- SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT03950271Phase 2
- CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor HistologyStatus unknownNCT03940846
- Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional AdenocarcinomaStatus unknownNCT03939962Phase 2
- Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube CancersTerminatedNCT03924245Phase 1
- High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic CancerWithdrawnNCT03908333Phase 1/2
- Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver GeneStatus unknownNCT03905317Phase 2
- Bevacizumab After Chemoradiotherapy For Locally Advanced Lung AdenocarcinomaCompletedNCT03904563Phase 2
- Factors Predicting Recurrence in Rectal Cancer After SurgeryCompletedNCT03899870
- Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic AdenocarcinomaWithdrawnNCT03891979Phase 4
- A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung AdenocarcinomaTerminatedNCT03891173Phase 2
- A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal AdenocarcinomaTerminatedNCT03890198Early Phase 1
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic AdenocarcinomaCompletedNCT03871959Phase 1
- Peptide-based Immunization for Colon- and and Pancreas-carcinomaCompletedNCT03871790
- A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal AdenocarcinomaTerminatedNCT03866239Phase 1